Mononuclear Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Corporate

  • Financing Rounds
  • 2

Mononuclear Therapeutics General Information

Description

Developer of cord blood mononuclear cell therapies designed for spinal cord injury, stroke and age-related macular degeneration. The company offers therapies which replace the ganglionic neurons that send axons into the optic nerve, promote the growth of axons across the injury and restore function in people with the chronic complete spinal cord, thereby helping patients by curing hematopoietic diseases including leukemia and lymphoma.

Contact Information

Website
www.monotx.com
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Unit 206, 16W, Hong Kong Science Park, Shatin
  • New Territories, Hong Kong
  • Hong Kong
  • Hong Kong
+852 3997
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Unit 206, 16W, Hong Kong Science Park, Shatin
  • New Territories, Hong Kong
  • Hong Kong
  • Hong Kong
+852 3997

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mononuclear Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Mononuclear Therapeutics‘s full profile, request access.

Request a free trial

Mononuclear Therapeutics Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 2

    Pending

  • Expiring in next 12 mo

Mononuclear Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026179461-A1 Use of umbilical cord blood exosomes in preparing medicament for treating aging-induced ophthalmic diseases Pending 28-Feb-2025
US-20240307452-A1 Umbilical cord blood mononuclear cells and red cell fraction improve neurogenesis and behavioral recovery after hypoxia-ischemic brain damage Pending 17-Jun-2021
WO-2022263928-A2 Umbilical cord blood mononuclear cells and red cell fraction improve neurogenesis and behavioral recovery after hypoxia-ischemic brain damage Inactive 17-Jun-2021
WO-2022263928-A8 Umbilical cord blood mononuclear cells and red cell fraction improve neurogenesis and behavioral recovery after hypoxia-ischemic brain damage Inactive 17-Jun-2021 A61K40/414

Mononuclear Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Mononuclear Therapeutics‘s full profile, request access.

Request a free trial

Mononuclear Therapeutics FAQs

  • When was Mononuclear Therapeutics founded?

    Mononuclear Therapeutics was founded in 2015.

  • Where is Mononuclear Therapeutics headquartered?

    Mononuclear Therapeutics is headquartered in Hong Kong, Hong Kong.

  • What industry is Mononuclear Therapeutics in?

    Mononuclear Therapeutics’s primary industry is Drug Discovery.

  • Is Mononuclear Therapeutics a private or public company?

    Mononuclear Therapeutics is a Private company.

  • What is Mononuclear Therapeutics’s current revenue?

    The current revenue for Mononuclear Therapeutics is .

  • Who are Mononuclear Therapeutics’s investors?

    EMA Aesthetics and The Innovation and Technology Commission have invested in Mononuclear Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process